Low-dose pioglitazone and low-dose flutamide added to metformin and oestro-progestagens for hyperinsulinaemic women with androgen excess: Add-on benefits disclosed by a randomized double-placebo study over 24 months

Clinical Endocrinology

Volumn 71, Issue 3, 2009, Pages 351-357

  Ibáñez, Lourdes ^a,b   López Bermejo, Abel ^c   Díaz, Marta ^a,b   Enríquez, Goya ^d   Del Río, Luis ^e   De Zegher, Francis ^f  

^a UNIVERSITY OF BARCELONA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c HOSPITAL JOSEP TRUETA   (Spain)

^d UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^e CETIR   (Spain)

^f UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ANDROGEN; DROSPIRENONE PLUS ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS NORELGESTROMIN; FLUTAMIDE; GLUCOSE; HIGH DENSITY LIPOPROTEIN; INSULIN; LOW DENSITY LIPOPROTEIN; METFORMIN; PIOGLITAZONE; PLACEBO; RETINOL BINDING PROTEIN 4; SOMATOMEDIN C; UNCLASSIFIED DRUG; VASPIN;

ABDOMINAL FAT; ABSORPTIOMETRY; ADD ON THERAPY; ADULT; ARTERIAL WALL THICKNESS; ARTICLE; BODY COMPOSITION; BODY MASS; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HYPERANDROGENISM; HYPERINSULINEMIA; INSULIN SENSITIVITY; INTRAABDOMINAL FAT; LOW DRUG DOSE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT OUTCOME;

ADOLESCENT; ANDROGEN ANTAGONISTS; ANDROGENS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FLUTAMIDE; HUMANS; HYPERINSULINISM; HYPOGLYCEMIC AGENTS; METFORMIN; PILOT PROJECTS; PROGESTINS; THIAZOLIDINEDIONES; YOUNG ADULT;

EID: 68949204550     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2008.03472.x     Document Type: Article

References (33)

1. Dunaif, A., Segal, K.R., Futterweit, W. et al. (1989) Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes, 38, 1165 1174.
2. Velazquez, E.M., Mendoza, S., Hamer, T. et al. (1994) Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism, 43, 647 654.
3. Nestler, J.E. Jakubowicz, D.J. (1997) Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17 α activity and serum androgens. Journal of Clinical Endocrinology and Metabolism, 82, 4075 4079.
4. Nestler, J.E., Jakubowicz, D.J., Evans, W.S. et al. (1998) Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. The New England Journal of Medicine, 338, 1876 1880.
5. Ibáñez, L., Valls, C., Potau, N. et al. (2000) Sensitization to insulin in adolescent girls to normalize hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism after precocious pubarche. Journal of Clinical Endocrinology and Metabolism, 85, 3526 3530.
6. Ibáñez, L., Valls, C., Ferrer, A. et al. (2001) Sensitization to insulin induces ovulation in nonobese adolescents with anovulatory hyperandrogenism. Journal of Clinical Endocrinology and Metabolism, 86, 3595 3598.
7. Ibáñez, L., Jaramillo, A.M., Ferrer, A. et al. (2005) High neutrophil count in girls and women with hyperinsulinaemic hyperandrogenism: normalization with metformin and flutamide overcomes the aggravation by oral contraception. Human Reproduction, 20, 2457 2462.
8. Ehrmann, D.A. (2005) Polycystic ovary syndrome. The New England Journal of Medicine, 352, 1223 1236.
9. Rosenfield, R.L. (2007) Clinical review: Identifying children at risk for polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism, 92, 787 796.
10. Ibáñez, L., Valls, C., Cabré, S. et al. (2004) Flutamide-metformin plus ethinylestradiol-drospirenone for lipolysis and antiatherogenesis in young women with ovarian hyperandrogenism: the key role of early, low-dose flutamide. Journal of Clinical Endocrinology and Metabolism, 89, 4716 4720.
11. Ibáñez, L. de Zegher, F. (2006) Low-dose flutamide-metformin therapy for hyperinsulinemic hyperandrogenism in non-obese adolescents and women. Human Reproduction Update, 12, 243 252.
12. Ibáñez, L., López-Bermejo, A., del Rio, L. et al. (2007) Combined low-dose pioglitazone, flutamide, and metformin for women with androgen excess. Journal of Clinical Endocrinology and Metabolism, 92, 1710 1714.
13. Ibáñez, L., López-Bermejo, A., Díaz, M. et al. (2008) Pioglitazone (7.5 mg/d) added to flutamide-metformin in women with androgen excess: additional increments of visfatin and high-molecular-weight adiponectin. Clinical Endocrinology, 68, 317 320.
14. Graham, T.E., Yang, Q., Blüher, M. et al. (2006) Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. The New England Journal of Medicine, 354, 2552 2563.
15. Lee, J.W., Im, J.A., Lee, H.R. et al. (2007) Visceral adiposity is associated with serum retinol binding protein-4 levels in healthy women. Obesity (Silver Spring), 15, 2225 2232.
16. Lee, D.C., Lee, J.W. Im, J.A. (2007) Association of serum retinol binding protein 4 and insulin resistance in apparently healthy adolescents. Metabolism, 56, 327 331.
17. Barber, T.M., Hazell, M., Christodoulides, C. et al. (2008) Serum levels of retinol-binding protein 4 and adiponectin in women with polycystic ovary syndrome: associations with visceral fat but no evidence for fat mass-independent effects on pathogenesis in this condition. Journal of Clinical Endocrinology and Metabolism, 93, 2859 2865.
18. Möhlig, M., Weickert, M.O., Ghadamgadai, E. et al. (2007) Adipocyte fatty acid-binding protein is associated with markers of obesity, but is an unlikely link between obesity, insulin resistance, and hyperandrogenism in polycystic ovary syndrome women. European Journal of Endocrinology, 157, 195 200.
19. Hutchison, S.K., Harrison, C., Stepto, N. et al. (2008) Retinol-Binding Protein 4 and insulin resistance in polycystic ovary syndrome. Diabetes Care, 31, 1427 1432.
20. Hida, K., Wada, J., Eguchi, J. et al. (2005) Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Procedures of the National Academy of Sciences USA, 102, 10610 10615.
21. Tan, B.K., Heutling, D., Chen, J. et al. (2008) Metformin decreases the adipokine vaspin in overweight women with the polycystic ovary syndrome: concomitant improvement in insulin sensitivity and a decrease in insulin resistance. Diabetes, 57, 1501 1507.
22. Ibáñez, L., Valls, C. de Zegher, F. (2006) Discontinuous low-dose flutamide-metformin plus an oral or a transdermal contraceptive in patients with hyperinsulinaemic hyperandrogenism: normalizing effects on CRP, TNF-α and the neutrophil-lymphocyte ratio. Human Reproduction, 21, 451 456.
23. Ibáñez, L. de Zegher, F. (2004) Ethinylestradiol- drospirenone, flutamide-metformin, or both for adolescents and women with hyperinsulinemic hyperandrogenism: opposite effects on adipocytokines and body adiposity. Journal of Clinical Endocrinology and Metabolism, 89, 1592 1597.
24. Ibáñez, L. de Zegher, F. (2004) Flutamide-metformin plus an oral contraceptive (OC) for young women with polycystic ovary syndrome: switch from third- to fourth-generation OC reduces body adiposity. Human Reproduction, 19, 1725 1727.
25. Ibáñez, L. de Zegher, F. (2005) Flutamide-metformin plus ethinylestradiol-drospirenone for lipolysis and antiatherogenesis in young women with ovarian hyperandrogenism: the key role of metformin at the start and after more than one year of therapy. Journal of Clinical Endocrinology and Metabolism, 90, 39 43.
26. De Leo, V., Lanzetta, D., D'Antona, D. et al. (1998) Hormonal effects of flutamide in young women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism, 83, 99 102.
27. Ibáñez, L., Potau, N., Marcos, M.V. et al. (2000) Treatment of hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism in nonobese, adolescent girls: effect of flutamide. Journal of Clinical Endocrinology and Metabolism, 85, 3251 3255.
28. Gambineri, A., Patton, L., Vaccina, A. et al. (2006) Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study. Journal of Clinical Endocrinology and Metabolism, 91, 3970 3980.
29. de Zegher, F. Ibáñez, L. (2009) Low-dose flutamide for women with androgen excess: anti-androgenic efficacy and hepatic safety. Journal of Endocrinological Investigation, 32, 83 84.
30. Tan, B.K., Tan, B.K., Chen, J. et al. (2007) Raised serum, adipocyte, and adipose tissue retinol-binding protein 4 in overweight women with polycystic ovary syndrome: effects of gonadal and adrenal steroids. Journal of Clinical Endocrinology and Metabolism, 92, 2764 2772.
31. Möhlig, M., Weickert, M.O., Ghadamgahi, E. et al. (2008) Retinol-binding protein 4 is associated with insulin resistance, but appears unsuited for metabolic screening in women with polycystic ovary syndrome. European Journal of Endocrinology, 158, 517 523.
32. Youn, B.S., Klöting, N., Kratzsch, J. et al. (2008) Serum vaspin concentrations in human obesity and type 2 diabetes. Diabetes, 57, 372 377.
33. Klöting, N., Berndt, J., Kralisch, S. et al. (2006) Vaspin gene expression in human adipose tissue: association with obesity and type 2 diabetes. Biochemical and Biophysical Research Communications, 339, 430 436.